Comparing Sonova (OTCMKTS:SONVY) & Rapid Micro Biosystems (NASDAQ:RPID)

Rapid Micro Biosystems (NASDAQ:RPID) and Sonova (OTCMKTS:SONVY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Institutional & Insider Ownership

52.6% of Rapid Micro Biosystems shares are held by institutional investors. Comparatively, 0.0% of Sonova shares are held by institutional investors. 30.0% of Rapid Micro Biosystems shares are held by company insiders. Comparatively, 0.0% of Sonova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Rapid Micro Biosystems has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Sonova has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Valuation & Earnings

This table compares Rapid Micro Biosystems and Sonova”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59 million	3.07	-$47.12 million	($1.07)	-2.12
Sonova	$4.36 billion	3.07	$610.01 million	N/A	N/A

Sonova has higher revenue and earnings than Rapid Micro Biosystems.

Analyst Ratings

This is a summary of current ratings and recommmendations for Rapid Micro Biosystems and Sonova, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1	0	1	0	2.00
Sonova	1	4	1	2	2.50

Rapid Micro Biosystems presently has a consensus price target of $8.00, indicating a potential upside of 252.42%. Given Rapid Micro Biosystems’ higher possible upside, equities research analysts plainly believe Rapid Micro Biosystems is more favorable than Sonova.

Profitability

This table compares Rapid Micro Biosystems and Sonova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-140.30%	-95.40%	-58.85%
Sonova	N/A	N/A	N/A

Summary

Sonova beats Rapid Micro Biosystems on 8 of the 12 factors compared between the two stocks.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About Sonova

Sonova Holding AG manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segments engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing implants and related products under the Advanced Bionics brand. The company sells its products through independent distributors; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.